Gilead Sciences, Inc.

Gilead Pharmasset LLC

Gilead Connecticut, Inc.

Roche Palo Alto LLC

Sierra Oncology, Inc.

Other

Glaxosmithkline LLC

Galapagos Nv

F. Hoffmann-la Roche Ag

Dimitrios Stefanidis

Rowchanak Pakdaman

Reza Oliyai

Vahid Zia

Bing Shi

Fang Wang

Ernest A Carra

Eric Gorman

Erik Mogalian

Jeffrey N Hemenway

Matthew Robert Warr

James Andrew Whitney

Melissa Jean Casteel

Yan Xin

Winston C Tse

Henry G Morrison

Bei Li

Lauren Wiser

John O Link

Michael Graupe

James Patrick Dunn

Jennifer R Zhang

Scott D Schroeder

Todd Richard Elworthy

Roland D Saito

Diana Sperger

Ben Chal

Brandon H Brown

Troy Reynolds

Zachary Kevin Sweeney

Adrian S Ray

Brandon Heath Brown

Charles William Rowe

Dragos Vizitiu

Darryl G Cleary

Hongmei Mo

Troy Evan Reynolds

Michael Laird Hurrey

Peter Chee-Chu Fung

Michael Thomas Brandl

Kondamraj Birudaraj

Tim G Elford

Charles J Reynolds

Miriam Michelle Berrey

Robert G Hindes

William T Symonds

Elham Nejati

Christy M Hebner

Steven J Henry

Navnit Hargovindas Shah

Wantanee Phuapradit

Joan Heather Hogg

Henry Morrison

Anna Chiu

Hashim Ahmed

Dana J Levine

Stephen R Yant

Scott P Sellers

Shridhar Hegde

Felix Sana

Thomas Vernon Alfredson

David Alonzo

Laura Elizabeth Bauer

Andrew Stephen Mulato

Martin Sunkwang Rhee

Hashim A Ahmed

Eric M Gorman

Shridar Hegde

The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Therapeutic compounds

Pharmaceutical compositions comprising filgotinib maleate Form I characterized by an XRPD pattern substantially the same as shown inand uses thereof are described herein.

Pharmaceutical compositions comprising a JAK inhibitor

The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Capsid inhibitors for the treatment of HIV

Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Combination formulation of two antiviral compounds

N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.

Combination formulation of three antiviral compounds

Polymorphs of a bis-mesylate salt of a compound of Formula I: or a hydrate thereof, are provided. The bis-mesylate salt may also be depicted as a compound of Formula IA: Provided herein are also compositions thereof, methods for their preparation and methods for such polymorphs.

Polymorph of Syk inhibitors

Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.

Growing community of inventors

Mountain View, CA, United States of America

Dimitrios Stefanidis